Cassava Sciences | PTIE - Current Assets


Cassava Sciences reported $87.96M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Cassava Sciences USD 87.96M 9.74M Mar/2026
Eisai JPY 761.64B 79.24B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Geron USD 498.53M 21.74M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Novavax USD 850.82M 127.46M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025